A Phase 1 Study to Assess the Feasibility of Non-invasive Dried Blood Sampling for Assessment of EDG-5506 Concentrations
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Sevasemten (Primary)
- Indications Muscular dystrophies
- Focus Pharmacokinetics
- Sponsors Edgewise Therapeutics
- 01 Sep 2022 Status changed from recruiting to completed.
- 12 Aug 2022 New trial record